Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: A gynecologic oncology group study

Cancer

Volumn 116, Issue 2, 2010, Pages 355-361

  Farley, John H ^a   Tian, Chunqiao ^b   Rose, G Scott ^a   Brown, Carol L ^c   Birrer, Michael ^d   Risinger, John I ^e   Thigpen, J Tate ^f   Fleming, Gini F ^g   Gallion, Holly H ^h   Maxwell, G Larry ⁱ  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Endometrial cancer; GOG

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADVANCED CANCER; AGE DISTRIBUTION; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUCASIAN; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEGRO; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

AFRICAN AMERICANS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 75649127632     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24769     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52:326-341.
3. Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer. 2007;110:234-243.
4. Hill HA, Eley JW, Harlan LC, Greenberg RS, Barrett RJ, 2nd, Chen VW. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol. 1996;88:919-926.
5. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176-186.
6. Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer. 1998;83:2629-2637.
7. Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health. 2004;94:2104-2111.
8. Randall TC, Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol. 2003;21:4200-426.
9. Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107:2197-2205.
10. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
11. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15:1173-118.
12. Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3808-3813.
13. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902-398.
14. Ziegler J, Citron M. Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nurs. 2006;29:266-272.
15. Lambrou N, Trimble EL. Dose-intensive approaches to ovarian cancer. Curr Oncol Rep. 1999;1:54-58.
16. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81:21-31.
17. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94:1160-117.
18. Tian C. Gastrointestinal toxicity in Gynecologic Oncology Group trials. In: GL M, ed. Buffalo, NY: Roswell Park; 2007.
19. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with earlystage breast cancer. J Clin Oncol. 2005;23:6639-6646.
20. Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol. 1997;176:S229-32.
21. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;175:1246-1252.
22. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6:2999-3005.
23. Ferguson SE, Olshen AB, Levine DA, Viale A, Barakat RR, Boyd J. Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol. 2006;101:209-213.
24. Maxwell GL CG, Dainty L, Litzi T, et al. Racial disparity in global gene expression among patients with advanced endometrial adenocarcinoma. Gynecol Oncol. 2005;96:927.
25. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25:517-525.
26. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol. 2007;25:4350-437.